{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:39:37Z","timestamp":1792449577490,"version":"4.5.0"},"reference-count":76,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005632","name":"National Centre for Research and Development","doi-asserted-by":"publisher","award":["POIR.01.01.01-00-0472\/19"],"award-info":[{"award-number":["POIR.01.01.01-00-0472\/19"]}],"id":[{"id":"10.13039\/501100005632","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.ejps.2025.107421","type":"journal-article","created":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T00:23:18Z","timestamp":1769732598000},"page":"107421","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation"],"prefix":"10.1016","volume":"219","author":[{"given":"Abdellah","family":"Yamani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawe\u0142","family":"Maliszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Pi\u00f3rkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrycja","family":"Olejkowska-Podg\u00f3rska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Pietru\u015b","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Luigi","family":"Naitana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Mitkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"\u0141aszek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delfina","family":"Popiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agata","family":"Miko\u0142ajczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Kornatowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kinga","family":"Jastrz\u0119bska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Mitu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Dominowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artur","family":"Janusz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"G\u00f3rka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Hucz-Kalitowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"Teska-Kami\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Sta\u0144czak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Delis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Damian","family":"Smuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerzy","family":"Pieczykolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Dubiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Wieczorek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.ejps.2025.107421_bib0001","article-title":"Prognostics and clinical outcomes in patients diagnosed with acute myeloid leukemia (AML) in a teaching hospital","volume":"13","author":"Alsulami","year":"2021","journal-title":"Cureus."},{"issue":"4","key":"10.1016\/j.ejps.2025.107421_bib0002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/106689690301100404","article-title":"Myeloid sarcoma: clinical and morphologic criteria useful for diagnosis","volume":"11","author":"Audouin","year":"2003","journal-title":"Int. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.ejps.2025.107421_bib0003","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1038\/s12276-022-00840-x","article-title":"BMS794833 inhibits macrophage efferocytosis by directly binding to MERTK and inhibiting its activity","volume":"54","author":"Bae","year":"2022","journal-title":"Exp. Mol. Med."},{"issue":"5","key":"10.1016\/j.ejps.2025.107421_bib0004","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.2010.30.1820","article-title":"Therapeutic advances in acute myeloid leukemia","volume":"29","author":"Burnett","year":"2011","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.ejps.2025.107421_bib0005","doi-asserted-by":"crossref","first-page":"7808","DOI":"10.1021\/jm9007533","article-title":"Identification of N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea dihydrochloride (AC220), a uniquely potent, selective, and efficacious FMS-like tyrosine kinase-3 (FLT3) inhibitor","volume":"52","author":"Chao","year":"2009","journal-title":"J. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejps.2025.107421_bib0006","doi-asserted-by":"crossref","first-page":"6190","DOI":"10.1021\/ja00772a043","article-title":"Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives","volume":"94","author":"Corey","year":"1972","journal-title":"J. Am. Chem. Soc."},{"issue":"39","key":"10.1016\/j.ejps.2025.107421_bib0007","doi-asserted-by":"crossref","first-page":"15700","DOI":"10.1021\/jacs.9b08660","article-title":"Data-driven construction of antitumor agents with controlled polypharmacology","volume":"141","author":"Da","year":"2019","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0008","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: a review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"issue":"W1","key":"10.1016\/j.ejps.2025.107421_bib0009","doi-asserted-by":"crossref","first-page":"W612","DOI":"10.1093\/nar\/gkv352","article-title":"ChEMBL web services: streamlining access to drug discovery data and utilities","volume":"43","author":"Davies","year":"2015","journal-title":"Nucleic. Acids. Res."},{"issue":"9544","key":"10.1016\/j.ejps.2025.107421_bib0010","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0011","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/0735-1097(96)00161-1","article-title":"Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion","volume":"28","author":"Dormans","year":"1996","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ejps.2025.107421_bib0012","first-page":"345","article-title":"Chapter 22-acute myeloid leukemia, NotOtherwise specified","author":"Faramarz","year":"2018","journal-title":"Atlas Hematopathol. (Second Ed.)"},{"issue":"13","key":"10.1016\/j.ejps.2025.107421_bib0013","doi-asserted-by":"crossref","first-page":"4372","DOI":"10.1182\/blood-2002-05-1440","article-title":"Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm","volume":"100","author":"Fr\u00f6hling","year":"2002","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejps.2025.107421_bib0014","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1182\/blood-2013-10-529313","article-title":"Crenolanib is a potent inhibitor of FLT3 with activity against resistance-conferring point mutants","volume":"123","author":"Galanis","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ejps.2025.107421_bib0015","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1080\/23808993.2017.1406798","article-title":"Midostaurin and emerging FLT3 inhibitors for the treatment of adults with newly diagnosed acute myeloid leukemia with the FLT3 mutation","volume":"2","author":"Gallogly","year":"2017","journal-title":"Expert. Rev. Precis. Med. Drug Dev."},{"issue":"100","key":"10.1016\/j.ejps.2025.107421_bib0016","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2002-02-0492","article-title":"The roles of FLT3 in hematopoiesis and leukemia","volume":"5","author":"Gilliland","year":"2002","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.ejps.2025.107421_bib0017","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"10.1016\/j.ejps.2025.107421_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236159","article-title":"Preclinical characterization of CPL302-253, a selective inhibitor of PI3K\u03b4, as the candidate for the inhalatory treatment and prevention of asthma. Rishi A","volume":"15","author":"Gunerka","year":"2020","journal-title":"PLoS. One"},{"issue":"10","key":"10.1016\/j.ejps.2025.107421_bib0019","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.clml.2016.06.002","article-title":"FLT3 Inhibitors for treating acute myeloid leukemia","volume":"16","author":"Hassanein","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.ejps.2025.107421_bib0020","doi-asserted-by":"crossref","unstructured":"Hastie, T., Tibshirani, R., Friedman, J., 2009. The elements of statistical learning, data mining, inference, and prediction, 2nd Edition. https:\/\/doi.org\/10.1007\/b94608.","DOI":"10.1007\/b94608"},{"issue":"9","key":"10.1016\/j.ejps.2025.107421_bib0021","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.3109\/10428194.2014.1001986","article-title":"Phase I dose escalation study of lestaurtinib in patients with myelofibrosis","volume":"56","author":"Hexner","year":"2015","journal-title":"Leuk. Lymphoma"},{"issue":"1","key":"10.1016\/j.ejps.2025.107421_bib0022","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/sj.leu.2401241","article-title":"Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia","volume":"13","author":"Iwai","year":"1999","journal-title":"Leukemia"},{"issue":"23","key":"10.1016\/j.ejps.2025.107421_bib0023","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140169","article-title":"TP-0903 is active in models of drug-resistant acute myeloid leukemia","volume":"5","author":"Jeon","year":"2020","journal-title":"JCI. Insight."},{"issue":"4","key":"10.1016\/j.ejps.2025.107421_bib0024","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1172\/JCI127907","article-title":"Targeting AML-associated FLT3 mutations with a type I kinase inhibitor","volume":"130","author":"Jones","year":"2020","journal-title":"J. Clin. Investig."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107421_bib0025","first-page":"7","article-title":"Flt3 inhibitors: recent advances and problems for clinical application","volume":"77","author":"Kiyoi","year":"2015","journal-title":"Nagoya J. Med. Sci."},{"issue":"3","key":"10.1016\/j.ejps.2025.107421_bib0026","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/sj.leu.2404508","article-title":"Antitumor activity of sorafenib in FLT3-driven leukemic cells","volume":"21","author":"Auclair","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2025.107421_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113892","article-title":"Investigation of chalcogen bioisosteric replacement in a series of heterocyclic inhibitors of tryptophan 2,3-dioxygenase","volume":"227","author":"Kozlova","year":"2022","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejps.2025.107421_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2020.127341","article-title":"Synthesis and anti-inflammatory activity of 2-oxo-2H-chromenyl and 2H-chromenyl-5-oxo-2,5-dihydrofuran-3-carboxylates","volume":"30","author":"Kurma","year":"2020","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0029","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1182\/blood-2016-10-745133","article-title":"Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor","volume":"129","author":"Lee","year":"2017","journal-title":"Blood"},{"issue":"46","key":"10.1016\/j.ejps.2025.107421_bib0030","doi-asserted-by":"crossref","first-page":"5359","DOI":"10.1038\/onc.2013.40","article-title":"Aberrant Mer receptor tyrosine kinase expression contributes to leukemogenesis in acute myeloid leukemia","volume":"32","author":"Lee-Sherick","year":"2013","journal-title":"Oncogene"},{"issue":"9","key":"10.1016\/j.ejps.2025.107421_bib0031","doi-asserted-by":"crossref","first-page":"6722","DOI":"10.18632\/oncotarget.3156","article-title":"Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia","volume":"6","author":"Lee-Sherick","year":"2015","journal-title":"Oncotarget."},{"issue":"11","key":"10.1016\/j.ejps.2025.107421_bib0032","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1182\/blood.V99.11.3885","article-title":"A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo","volume":"99","author":"Levis","year":"2002","journal-title":"Blood"},{"issue":"2A","key":"10.1016\/j.ejps.2025.107421_bib0033","first-page":"1201","article-title":"FLT3 Overexpression in acute promyelocytic leukemia patients without detectable FLT3-ITD or Codon 835-836 mutations: a pilot study","volume":"26","author":"Lilakos","year":"2006","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejps.2025.107421_bib0034","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0065-230X(08)00002-X","article-title":"TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer","volume":"100","author":"Linger","year":"2008","journal-title":"Adv. Cancer Res."},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0035","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1021\/ml200239k","article-title":"Discovery of novel small molecule mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia","volume":"3","author":"Liu","year":"2012","journal-title":"ACS. Med. Chem. Lett."},{"issue":"14","key":"10.1016\/j.ejps.2025.107421_bib0036","doi-asserted-by":"crossref","first-page":"7721","DOI":"10.1021\/acs.jmedchem.0c00564","article-title":"Nitrogen-walk approach to explore bioisosteric replacements in a series of potent A2B adenosine receptor antagonists","volume":"63","author":"Mallo-Abreu","year":"2020","journal-title":"J. Med. Chem."},{"issue":"10","key":"10.1016\/j.ejps.2025.107421_bib0037","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.3390\/cancers14102488","article-title":"Two-front war on cancer-targeting TAM receptors in solid tumour therapy","volume":"14","author":"Mikolajczyk","year":"2022","journal-title":"Cancers. (Basel)"},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0038","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/reactions1020005","article-title":"Synthesis of 2-benzylidene-3-pyrrolines and their synthetic transformation","volume":"1","author":"Ming-Tsung","year":"2020","journal-title":"Reactions. (Basel)"},{"issue":"3","key":"10.1016\/j.ejps.2025.107421_bib0039","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.85630","article-title":"The MERTK\/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia","volume":"1","author":"Minson","year":"2016","journal-title":"JCI. Insight."},{"issue":"36","key":"10.1016\/j.ejps.2025.107421_bib0040","doi-asserted-by":"crossref","first-page":"3437","DOI":"10.1016\/S0040-4039(01)95429-2","article-title":"A new stereospecific cross-coupling by the palladium-catalyzed reaction of 1-alkenyl boranes with 1-alkenyl or 1-alkynyl halides","volume":"20","author":"Miyaura","year":"1979","journal-title":"Tetrahedron. Lett."},{"issue":"5","key":"10.1016\/j.ejps.2025.107421_bib0041","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s10637-017-0470-z","article-title":"Gilteritinib, a FLT3\/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia","volume":"35","author":"Mori","year":"2017","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.ejps.2025.107421_bib0042","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.2147\/OTT.S101385","article-title":"Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives","volume":"9","author":"Mulet-Margalef","year":"2016","journal-title":"Onco Targets. Ther."},{"key":"10.1016\/j.ejps.2025.107421_bib0043","doi-asserted-by":"crossref","first-page":"n2026","DOI":"10.1136\/bmj.n2026","article-title":"Advances in acute myeloid leukemia","volume":"375","author":"Newell","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.ejps.2025.107421_bib0044","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O'Farrell","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107421_bib0045","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.ebiom.2019.01.019","article-title":"Prediction of ALK mutations mediating ALK-TKIs resistance and drug re-purposing to overcome the resistance","volume":"41","author":"Okada","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/j.ejps.2025.107421_bib0046","unstructured":"Pearson Correlation Coefficient Calculator (https:\/\/www.socscistatistics.com\/tests\/pearson\/#google_vignette)."},{"key":"10.1016\/j.ejps.2025.107421_bib0047","first-page":"2825","article-title":"Scikit-learn: machine learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"issue":"22","key":"10.1016\/j.ejps.2025.107421_bib0048","doi-asserted-by":"crossref","first-page":"4443","DOI":"10.1042\/BCJ20200735","article-title":"A-loop interactions in Mer tyrosine kinase give rise to inhibitors with two-step mechanism and long residence time of binding","volume":"477","author":"Pflug","year":"2020","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejps.2025.107421_bib0049","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1293728","article-title":"Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer","volume":"13","author":"Popiel","year":"2024","journal-title":"Front. Oncol."},{"issue":"7","key":"10.1016\/j.ejps.2025.107421_bib0050","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1182\/blood-2009-09-242859","article-title":"FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML","volume":"115","author":"Pratz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107421_bib0051","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1021\/ci100050t","article-title":"Extended-connectivity fingerprints","volume":"50","author":"Rogers","year":"2010","journal-title":"J. Chem. Inf. Model."},{"issue":"12","key":"10.1016\/j.ejps.2025.107421_bib0052","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.3324\/haematol.2017.168856","article-title":"Anexelekto\/MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms","volume":"102","author":"Ruvolo","year":"2017","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.ejps.2025.107421_bib0053","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jct.2010.01.009","article-title":"Experimental and computational thermochemistry of 1-phenylpyrrole and 1-(4-methylphenyl)pyrrole","volume":"42","author":"Santos","year":"2010","journal-title":"J. Chem. Thermodyn."},{"issue":"11","key":"10.1016\/j.ejps.2025.107421_bib0054","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.3390\/cells9112493","article-title":"Molecular mechanisms of resistance to FLT3 inhibitors in acute myeloid leukemia: ongoing challenges and future treatments","volume":"9","author":"Scholl","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ejps.2025.107421_bib0055","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1517\/13543781003598862","article-title":"Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside","volume":"19","author":"Shabbir","year":"2010","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"10.1016\/j.ejps.2025.107421_bib0056","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2040620719827310","article-title":"Emerging treatment paradigms with FLT3 inhibitors in acute myeloid leukemia","volume":"10","author":"Short","year":"2019","journal-title":"Ther. Adv. Hematol."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107421_bib0057","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0022-328X(02)01158-0","article-title":"Development of Pd\u2013Cu catalyzed cross-coupling of terminal acetylenes with sp2 -carbon halides","volume":"653","author":"Sonogashira","year":"2002","journal-title":"J. Organomet. Chem."},{"issue":"9","key":"10.1016\/j.ejps.2025.107421_bib0058","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1038\/leu.2012.115","article-title":"Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia","volume":"26","author":"Stone","year":"2012","journal-title":"Leukemia"},{"issue":"19","key":"10.1016\/j.ejps.2025.107421_bib0059","doi-asserted-by":"crossref","first-page":"14046","DOI":"10.1021\/acs.jmedchem.1c01215","article-title":"Bioisosteres of the phenyl ring: recent strategic applications in lead optimization and drug design","volume":"64","author":"Subbaiah","year":"2021","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.ejps.2025.107421_bib0060","doi-asserted-by":"crossref","first-page":"277","DOI":"10.20546\/ijcrar.2016.402.031","article-title":"1, 2, 4-Triazole scaffolds: recent advances and pharmacological applications","volume":"4","author":"Thakur","year":"2016","journal-title":"Int. J. Curr. Res. Aca. Rev."},{"key":"10.1016\/j.ejps.2025.107421_bib0061","doi-asserted-by":"crossref","unstructured":"Thomas, C.J. 2018. Crystal structure of the FLT3 kinase bound to a small molecule inhibitor. RCSB PDB - 6IL3. https:\/\/doi.org\/10.2210\/pdb6IL3\/pdb.","DOI":"10.2210\/pdb6il3\/pdb"},{"issue":"10","key":"10.1016\/j.ejps.2025.107421_bib0062","doi-asserted-by":"crossref","first-page":"961","DOI":"10.4155\/fmc-2019-0365","article-title":"Recent advances in FLT3 inhibitors for acute myeloid leukemia","volume":"12","author":"Tong","year":"2020","journal-title":"Fut. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107421_bib0063","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"21","key":"10.1016\/j.ejps.2025.107421_bib0064","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1182\/blood.V118.21.1519.1519","article-title":"A novel dual AXL\/Mertk and aurora kinase inhibitor active against T cell acute lymphoblastic leukemia","volume":"118","author":"Verma","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejps.2025.107421_bib0065","first-page":"495s","article-title":"National surgical adjuvant breast and bowel project update: prevention trials and endocrine therapy of ductal carcinoma in situ","volume":"9","author":"Vogel","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.ejps.2025.107421_bib0066","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.chroma.2005.10.030","article-title":"High-throughput screening of protein binding by equilibrium dialysis combined with liquid chromatography and mass spectrometry","volume":"1102","author":"Wan","year":"2006","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.ejps.2025.107421_bib0067","doi-asserted-by":"crossref","first-page":"26579","DOI":"10.1021\/acsanm.4c04940","article-title":"Machine learning-driven multidomain nanomaterial design: from bibliometric analysis to applications","volume":"7","author":"Wang","year":"2024","journal-title":"ACS. Appl. Nano Mater."},{"key":"10.1016\/j.ejps.2025.107421_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.cis.2025.103671","article-title":"Accelerating the discovery and optimization of metal-organic framework materials via machine learning","volume":"346","author":"Wang","year":"2025","journal-title":"Adv. Colloid. Interface Sci."},{"issue":"7","key":"10.1016\/j.ejps.2025.107421_bib0069","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1038\/onc.2012.104","article-title":"Mer receptor tyrosine kinase promotes invasion and survival in glioblastoma multiforme","volume":"32","author":"Wang","year":"2013","journal-title":"Oncogene"},{"issue":"10","key":"10.1016\/j.ejps.2025.107421_bib0070","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.ejps.2025.107421_bib0071","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/leu.2016.297","article-title":"MZH29 is a novel potent inhibitor that overcomes drug resistance FLT3 mutations in acute myeloid leukemia","volume":"31","author":"Xu","year":"2017","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.ejps.2025.107421_bib0072","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1182\/blood.V97.8.2434","article-title":"Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies","volume":"97","author":"Yamamoto","year":"2001","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejps.2025.107421_bib0073","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1182\/blood-2017-05-786657","article-title":"A novel irreversible FLT3 inhibitor, FF-10101, shows excellent efficacy against AML cells with FLT3 mutations","volume":"131","author":"Yamaura","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2025.107421_bib0074","article-title":"Machine learning applications in nanomaterials: recent advances and future perspectives","volume":"500","author":"Yang","year":"2024","journal-title":"Chem. Eng. J."},{"issue":"16","key":"10.1016\/j.ejps.2025.107421_bib0075","doi-asserted-by":"crossref","first-page":"7031","DOI":"10.1021\/jm500749d","article-title":"UNC2025, a potent and orally bioavailable MER\/FLT3 dual inhibitor","volume":"57","author":"Zhang","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejps.2025.107421_bib0076","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113534","article-title":"UNC5293, a potent, orally available and highly MERTK-selective inhibitor","volume":"220","author":"Zheng","year":"2021","journal-title":"Eur. J. Med. Chem."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500418X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S092809872500418X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T12:36:32Z","timestamp":1773664592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S092809872500418X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":76,"alternative-id":["S092809872500418X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107421","relation":{},"ISSN":["0928-0987"],"issn-type":[{"value":"0928-0987","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of pyrrolo[2,3-d]pyrimidine-based dual MERTK and FLT3 inhibitor: Hit-to-lead, machine learning, modeling, synthesis, and biological evaluation","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2025.107421","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107421"}}